Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Gemcitabine 78Cisplatin 55pembrolizumab 31Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 12Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × Tablets × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡